Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other financing activities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other financing activities for 11 consecutive years, with $678000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities rose 70.78% to $678000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 3.33% increase, with the full-year FY2024 number at $2.7 million, up 6.36% from a year prior.
  • Other financing activities was $678000.0 for Q3 2025 at Theravance Biopharma, up from $503000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $23.6 million in Q4 2022 to a low of -$26.5 million in Q3 2022.
  • A 5-year average of $757600.0 and a median of $677000.0 in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: plummeted 74.11% in 2022, then surged 101.93% in 2023.
  • Theravance Biopharma's Other financing activities stood at $5.6 million in 2021, then surged by 322.65% to $23.6 million in 2022, then crashed by 97.83% to $512000.0 in 2023, then soared by 32.23% to $677000.0 in 2024, then increased by 0.15% to $678000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other financing activities are $678000.0 (Q3 2025), $503000.0 (Q2 2025), and $874000.0 (Q1 2025).